Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Portrait Mobile Monitoring Solution V2.0 External Evaluation

NCT07309809 · tracked via the Priya Life Science UK tracker
Phase
Not applicable
Started
2026-07
Last updated
2026-06-10

Condition(s) studied

Monitoring

Investigational drug(s) / intervention(s)

Continuous Monitoring

Continuous Monitoring: Subjects will have vital signs continuously monitored for up to 72 hours with the study device

Study summary

The purpose of this study is to collect and assess feedback from the users regarding the functionality and performance of the Portrait Mobile Monitoring Solution V2.0. In addition, this study aims to collect raw parameter data from the investigational devices for use in current and future Portrait Mobile development, including engineering purposes as deemed appropriate by the Sponsor.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Participant is age 18 years or older (≥18 years). 2. Participant must have the ability to understand and provide written informed consent. 3. Are being cared for in a hospital unit and are expected to remain in the unit for the duration of the study procedure. 4. Participant must be willing and able to comply with study procedures and duration. Exclusion Criteria: 1. Known to be pregnant and/or breast feeding. 2. Diagnosed with infection requiring isolation. 3. Are immunocompromised. 4. Have previously participated in this study (no subject may participate more than once). 5. Subjects with Implantable Minute Ventilation Rate Responsive Pacemakers should be excluded from respiration rate monitoring.

Primary outcome measure(s)

  • Collection of user feedback surveys from Clinicians — Up to 72 hours
    Number of clinician feedback surveys collected at the end of each shift for clinicians overseeing care of subjects receiving continuous vital signs monitoring.
  • Collection of Subject Survey — up to 72 hours
    Number of subject surveys collected from study participants at the end of their continuous monitoring

Trial sites (1)

FacilityCityRegionStatus
West Middlesex University Hospital London England
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07309809 on ClinicalTrials.gov ↗ ← All trials in the UK